

Michael A Postow

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4008252/michael-a-postow-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

134
papers

32,314
citations

59
h-index

143
g-index

143
ext. papers

39,750
ext. citations

13.9
avg, IF

7.24
L-index

#	Paper	IF	Citations
134	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
133	Nivolumab plus ipilimumab in advanced melanoma. <i>New England Journal of Medicine</i> , 2013 , 369, 122-33	59.2	3118
132	Genetic basis for clinical response to CTLA-4 blockade in melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 2189-2199	59.2	2802
131	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
130	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. <i>New England Journal of Medicine</i> , 2015 , 372, 2006-17	59.2	2001
129	Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2018 , 378, 158-168	59.2	1834
128	Immunologic correlates of the abscopal effect in a patient with melanoma. <i>New England Journal of Medicine</i> , 2012 , 366, 925-31	59.2	1503
127	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet, The</i> , 2014 , 384, 1109-17	40	1340
126	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017 , 545, 60-65	50.4	850
125	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	699
124	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3193-8	2.2	697
123	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018 , 379, 722-730	59.2	659
122	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1558-1568	21.7	627
121	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 709-717	2.2	587
120	Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. <i>JAMA Oncology</i> , 2016 , 2, 1346-1353	13.4	493
119	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016 , 22, 5487-5496	12.9	373
118	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 2908-18	12.9	372

117	Immune modulation in cancer with antibodies. <i>Annual Review of Medicine</i> , 2014 , 65, 185-202	17.4	366
116	Targeting T Cell Co-receptors for Cancer Therapy. <i>Immunity</i> , 2016 , 44, 1069-78	32.3	314
115	Managing immune checkpoint-blocking antibody side effects. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 76-83	7.1	271
114	Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 368-75	4	268
113	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3807-3814	2.2	264
112	Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3826-33	2.2	234
111	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	227
110	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016 , 4, 383-9	12.5	199
109	Checkpoint blocking antibodies in cancer immunotherapy. <i>FEBS Letters</i> , 2014 , 588, 368-76	3.8	184
108	LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. <i>Cell</i> , 2018 , 172, 825-840.e18	56.2	181
107	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. <i>Cancer Treatment Reviews</i> , 2017 , 58, 70-76	14.4	173
106	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. <i>Oncologist</i> , 2016 , 21, 1230-1240	5.7	165
105	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016 , 122, 3354-3362	6.4	164
104	The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1490-1493	11.6	156
103	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. <i>Nature</i> , 2015 , 526, 453-7	50.4	144
102	Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. <i>Cancer</i> , 2013 , 119, 3687-95	6.4	143
101	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. <i>Frontiers in Oncology</i> , 2014 , 4, 385	5.3	135
100	Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma 2015 , 3, 23		134

99	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015 , 25, 208-24	24.7	126
98	Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. <i>Cancer Immunology Research</i> , 2013 , 1, 92-8	12.5	118
97	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 391-398	2.2	118
96	Ipilimumab for patients with advanced mucosal melanoma. <i>Oncologist</i> , 2013 , 18, 726-32	5.7	117
95	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016 , 21, 848-54	5.7	115
94	On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. <i>Science Translational Medicine</i> , 2015 , 7, 280sr1	17.5	113
93	Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 986-97	4	112
92	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 4848-4858	12.9	108
91	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018 , 4, 98-101	13.4	98
90	Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. <i>Cancer Immunology Research</i> , 2014 , 2, 812-21	12.5	97
89	Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019 , 25, 759-766	50.5	95
88	Mucosal melanoma: pathogenesis, clinical behavior, and management. <i>Current Oncology Reports</i> , 2012 , 14, 441-8	6.3	93
87	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , 2019 , 20, e378-e389	21.7	88
86	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy 2017 , 5, 8		86
85	First-in-Humans Imaging with Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 512-519	8.9	86
84	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2746-2758	2.2	84
83	Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018 , 33, 1017-1032.e7	24.3	81
82	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment 2017 , 5, 76		78

81	Opportunistic infections in patients treated with immunotherapy for cancer 2014 , 2, 19		78
80	Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1655-1663	2.2	72
79	Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3925-3930	5.6	71
78	Ipilimumab in patients with melanoma and autoimmune disease 2014 , 2, 35		70
77	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. <i>EBioMedicine</i> , 2017 , 18, 56-61	8.8	67
76	Immune checkpoint modulation: rational design of combination strategies. <i>Pharmacology & Therapeutics</i> , 2015 , 150, 23-32	13.9	62
75	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017 , 73, 61-70	7.5	59
74	Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. <i>Ophthalmology</i> , 2017 , 124, 1788-1798	7.3	59
73	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021 , 27, 1432-1441	50.5	57
72	Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. <i>Cancer Medicine</i> , 2018 , 7, 690-697	4.8	56
71	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017 , 82, 80-91	7.5	55
70	High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. <i>Cancer</i> , 2020 , 126, 76-85	6.4	46
69	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. <i>Head and Neck</i> , 2016 , 38, 1310-7	4.2	46
68	Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Infectious Diseases</i> , 2020 , 70, 193-199	11.6	44
67	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021 , 12, 729	17.4	44
66	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	41
65	Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. <i>Clinical Sarcoma Research</i> , 2012 , 2, 16	2.5	40
64	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021 , 53, 11-15	36.3	38

63	Proportions of blood-borne V β 1+ and V β 2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2016 , 64, 116-26	7.5	36
62	Checkpoint Blockade for the Treatment of Advanced Melanoma. <i>Cancer Treatment and Research</i> , 2016 , 167, 231-50	3.5	33
61	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016 , 18, 21	6.3	32
60	Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1239-1253	4.5	30
59	Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. <i>Melanoma Research</i> , 2017 , 27, 57-64	3.3	27
58	The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?. <i>Clinical Cancer Research</i> , 2012 , 18, 1821-3	12.9	24
57	Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 372-8	2.2	24
56	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021 , 23, 1961-1973	19.7	24
55	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3350-3358	2.2	23
54	Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 153-9	2.2	23
53	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2021 , 22, 1692-1704	21.7	23
52	Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1989-1996	3.1	22
51	Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. <i>Oncologist</i> , 2020 , 25, 140-149	5.7	22
50	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. <i>Oncologist</i> , 2019 , 24, e196-e197	5.7	22
49	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1180-1188	3.1	21
48	Safety of Infusing Ipilimumab Over 30 Minutes. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3454-8	2.2	19
47	Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. <i>Journal of Translational Medicine</i> , 2014 , 12, O8	8.5	17
46	Checkpoint modulation in melanoma: an update on ipilimumab and future directions. <i>Current Oncology Reports</i> , 2013 , 15, 500-8	6.3	17

45	Liver resection and ablation for metastatic melanoma: A single center experience. <i>Journal of Surgical Oncology</i> , 2015 , 111, 962-8	2.8	16
44	A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 3193-3201	12.9	14
43	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	14
42	A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10003-10003	2.2	13
41	Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. <i>Melanoma Research</i> , 2020 , 30, 71-75	3.3	12
40	Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. <i>Cancer</i> , 2021 , 127, 2062-2073	6.4	12
39	Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. <i>British Journal of Haematology</i> , 2015 , 171, 84-90	4.5	11
38	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. <i>Cell</i> , 2022 , 185, 563-575.e11	56.2	11
37	A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9600-TPS9600	2.2	11
36	Intravitreal Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. <i>Ophthalmology</i> , 2020 , 127, 240-248	7.3	11
35	Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. <i>Experimental Dermatology</i> , 2016 , 25, 553-4	4	11
34	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2021 ,	44.5	10
33	Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. <i>Clinical Cancer Research</i> , 2018 , 24, 730-736	12.9	8
32	Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy: A Report of 2 Cases. <i>JAMA Dermatology</i> , 2019 , 155, 347-352	5.1	8
31	Computed tomography-derived assessments of regional muscle volume: Validating their use as predictors of whole body muscle volume in cancer patients. <i>British Journal of Radiology</i> , 2018 , 91, 20180451	2.4	8
30	Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017 , 25, 2155-2167	3.9	7
29	Imaging findings of immune checkpoint inhibitor associated pancreatitis. <i>European Journal of Radiology</i> , 2020 , 131, 109250	4.7	7
28	Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. <i>Oncotarget</i> , 2017 , 8, 105000-105010	3.3	6

27	Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma. <i>Methods in Molecular Biology</i> , 2014 , 1102, 83-95	1.4	6
26	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. <i>Clinical Cancer Research</i> , 2021 , 27, 2226-2235	12.9	6
25	A step forward for patients with NRAS-mutant melanoma. <i>Lancet Oncology, The</i> , 2017 , 18, 414-415	21.7	5
24	Current options and future directions in the systemic treatment of metastatic melanoma. <i>Journal of Community and Supportive Oncology</i> , 2014 , 12, 20-6		5
23	Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 820-822	9.7	5
22	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.. <i>Frontiers in Immunology</i> , 2021 , 12, 810388	8.4	4
21	TNFBlockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?. <i>Clinical Cancer Research</i> , 2020 , 26, 2085-2086	12.9	3
20	The brim of uncertainty in adjuvant treatment of melanoma. <i>Lancet Oncology, The</i> , 2018 , 19, 436-437	21.7	3
19	Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.. <i>JAMA Oncology</i> , 2022 ,	13.4	3
18	Dermatologic infections in cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 1528-1536	4.5	3
17	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade 2021 , 9,		3
16	Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	3
15	Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. 2022 , 10,		2
14	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101570	2.2	2
13	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. <i>Clinical Cancer Research</i> , 2021 , 27, 1516-1525	12.9	2
12	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 2021 , 9,		2
11	Immune-Directed Molecular Imaging Biomarkers. <i>Seminars in Nuclear Medicine</i> , 2020 , 50, 584-603	5.4	2
10	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. <i>Onc Immunology</i> , 2021 , 10, 1898105	7.2	2

9	Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015 , 2, 339-352	2.1	1
8	Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?. <i>Lancet Oncology, The</i> , 2017 , 18, 1144-1145	21.7	1
7	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab 2021 , 9,		1
6	Reply to M. Horiguchi et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 721	2.2	1
5	Chemotherapy in the Rwandan countryside: universal issues a world away. <i>Annals of Internal Medicine</i> , 2012 , 156, 60-1	8	0
4	Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series.. <i>Oncologist</i> , 2022 , 27, e350-e352	5.7	
3	Primary Mucosal Melanomas of the Head and Neck 2016 , 641-656		
2	Reply to A. Indini et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1018-9	2.2	
1	The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.. <i>Journal of Translational Medicine</i> , 2022 , 20, 179	8.5	